The U.K. government has announced that the use of puberty blockers for adolescents under 18 will remain banned indefinitely, with some exceptions for clinical trials. Health Secretary Wes Streeting emphasized the need to prioritize the safety of young people, citing medical experts' warnings about the risks involved in prescribing these treatments without thorough research.
The ban seeks to provide caution for this vulnerable demographic as a clinical trial is set to take place next year to establish a clearer evidence base for the administration of puberty blockers. This decision extends across England, Scotland, Wales, and Northern Ireland and follows a review led by pediatrician Hilary Cass, which raised concerns about the reliability of current transgender treatment practices.
The National Health Service (NHS) has halted routine prescriptions of puberty blockers for minors as part of its efforts to ensure better understanding and safety in treatments related to gender dysphoria.
The ban seeks to provide caution for this vulnerable demographic as a clinical trial is set to take place next year to establish a clearer evidence base for the administration of puberty blockers. This decision extends across England, Scotland, Wales, and Northern Ireland and follows a review led by pediatrician Hilary Cass, which raised concerns about the reliability of current transgender treatment practices.
The National Health Service (NHS) has halted routine prescriptions of puberty blockers for minors as part of its efforts to ensure better understanding and safety in treatments related to gender dysphoria.
